OR WAIT null SECS
The company announced that participants have enrolled in a Phase 1/2 clinical trial of its COVID-19 vaccine candidate, NVX‑CoV2373, a prefusion protein made using Novavax’s proprietary nanoparticle technology.
Novavax, a late-stage biotechnology company located in Gaithersburg, MD, announced on May 25, 2020 that participants have enrolled in a Phase 1/2 clinical trial of its COVID-19 vaccine candidate, NVXâCoV2373, a prefusion protein made using Novavax’s proprietary nanoparticle technology.
According to a company press release, the Phase 1 portion of the trial is a randomized, observer-blinded, placebo-controlled trial to determine the immunogenicity and safety of the vaccine candidate using a two-dose trial regimen with MatrixâM and without. The Phase 2 section will take place in several countries and will assess immunity, safety, and the COVIDâ19 disease reduction associated with the candidate.
Novavax selected NVXâCoV2373 as its lead COVID-19 candidate after preclinical testing showed high immunogenicity and high levels of neutralizing antibodies, the press release said.
“Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the fundamental need for a vaccine in the fight against the global COVIDâ19 pandemic,” said Stanley C. Erck, president and CEO of Novavax, in the press release. “We look forward to sharing the clinical results in July and, if promising, quickly initiating the Phase 2 portion of the trial.”